Limits...
Insulin-egg yolk dispersions in self microemulsifying system.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Bottom Line: The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %.Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Formulation of insulin into a microemulsion very often presents a physicochemical instability during their preparation and storage. In order to overcome this lack of stability and facilitate the handling of these colloidal systems, stabilization of insulin in presence of hydrophobic components of a microemulsion appears as the most promising strategy. The present paper reports the use of egg yolk for stabilization of insulin in self microemulsifying dispersions. Insulin loaded egg yolk self microemulsifying dispersions were prepared by lyophilization followed by dispersion into self microemulsifying vehicle. The physicochemical characterization of selfmicroemulsifying dispersions includes such as insulin encapsulation efficiency, in vitro stability of insulin in presence of proteolytic enzymes and in vitro release. The biological activity of insulin from the dispersion was estimated by enzyme-linked immunosorbant assay and in vivo using Wistar diabetic rats. The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %. Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.


Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3040865&req=5

Figure 0004: Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.

Mentions: Hypoglycemic effect from InsEY-SMEDS dispersions was found to considerably higher than the placebo control group, however the extent of plasma glucose concentration reduction was highest with subcutaneous injection of human insulin solution. The reduction in the plasma glucose concentration was observed over the period of 4 to 12 h (fig. 4). Hypoglycemic effect of the 20 IU/kg dose was lower than 2 IU/kg subcutaneous injection of human insulin injection with respect to the extent of reduction in glucose concentration from base line (∼31% for 20 IU/kg, intragastrically administered human insulin InsEY-SMEDS and ∼73.5 % of baseline for 2 IU/kg subcutaneously injected human Insulin solution). Area above glucose concentration curves, AAC0-12h calculated from these curves (fig. 4). AAC0-12h of both the formulations depicted in fig. 5 show that the effect of 20 IU/kg dose of InsEY-SMEDS formulation was lower than subcutaneous injection of 2 IU/kg insulin, while the effect of the latter was diminished at 6 h after injection the former seemed to be continuing its hypoglycemic activity.


Insulin-egg yolk dispersions in self microemulsifying system.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3040865&req=5

Figure 0004: Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.
Mentions: Hypoglycemic effect from InsEY-SMEDS dispersions was found to considerably higher than the placebo control group, however the extent of plasma glucose concentration reduction was highest with subcutaneous injection of human insulin solution. The reduction in the plasma glucose concentration was observed over the period of 4 to 12 h (fig. 4). Hypoglycemic effect of the 20 IU/kg dose was lower than 2 IU/kg subcutaneous injection of human insulin injection with respect to the extent of reduction in glucose concentration from base line (∼31% for 20 IU/kg, intragastrically administered human insulin InsEY-SMEDS and ∼73.5 % of baseline for 2 IU/kg subcutaneously injected human Insulin solution). Area above glucose concentration curves, AAC0-12h calculated from these curves (fig. 4). AAC0-12h of both the formulations depicted in fig. 5 show that the effect of 20 IU/kg dose of InsEY-SMEDS formulation was lower than subcutaneous injection of 2 IU/kg insulin, while the effect of the latter was diminished at 6 h after injection the former seemed to be continuing its hypoglycemic activity.

Bottom Line: The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %.Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Formulation of insulin into a microemulsion very often presents a physicochemical instability during their preparation and storage. In order to overcome this lack of stability and facilitate the handling of these colloidal systems, stabilization of insulin in presence of hydrophobic components of a microemulsion appears as the most promising strategy. The present paper reports the use of egg yolk for stabilization of insulin in self microemulsifying dispersions. Insulin loaded egg yolk self microemulsifying dispersions were prepared by lyophilization followed by dispersion into self microemulsifying vehicle. The physicochemical characterization of selfmicroemulsifying dispersions includes such as insulin encapsulation efficiency, in vitro stability of insulin in presence of proteolytic enzymes and in vitro release. The biological activity of insulin from the dispersion was estimated by enzyme-linked immunosorbant assay and in vivo using Wistar diabetic rats. The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %. Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.